Amgen

This study tested a drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare condition that causes skin thickening and can affect the lungs. Participants took either a low dose, a high dose, or a placebo for 52 weeks. The trial was stopped early, …

This study tested an experimental drug called HZN-825 in people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing hard. The trial aimed to see if the drug could slow the decline in lung function over 52 weeks. About 153 adul…

This early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goal was to check safety and find the right dose. The trial was stopped early after enrolling only 3 participant…

This study tested a new drug called efavaleukin alfa for people with moderate to severe ulcerative colitis, a chronic bowel disease. Participants received one of three doses of the drug or a placebo for 12 weeks, with an option to continue treatment for up to a year. The goal was…

This early-stage trial tested a drug called AMG 420 in 23 people with multiple myeloma, a type of blood cancer, that had come back or stopped responding to prior treatments. The goal was to find the safest dose and check for side effects. The study was stopped early, and results …

This early-stage study tested a new drug called acapatamab in 212 men with metastatic castration-resistant prostate cancer that had stopped responding to standard therapies. The drug works by helping the body's immune cells attack cancer cells that have a specific marker (PSMA) o…

This study tested a drug called HZN-825 in people with diffuse cutaneous systemic sclerosis, a rare disease that causes skin thickening and can harm internal organs. The goal was to see if the drug could improve lung function and was safe over 52 weeks. The trial was terminated e…

This study tested an experimental drug called AMG 701, alone or with other medicines, in 174 adults with multiple myeloma that returned or stopped responding to prior treatments. The main goal was to check safety and find the right dose. The trial was terminated early, so results…

This study tested an experimental drug, HZN-1116, in 209 adults with Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The goal was to see if the drug could reduce disease activity and symptoms. However, the trial was terminated early, so results are not avail…

This study looked at the long-term safety of an experimental drug called efavaleukin alfa for people with moderate to severe ulcerative colitis. It was designed for patients who had already completed a one-year study and might benefit from continued treatment. However, the study …

This early-stage study tested a new drug called AMG 199 in adults with advanced stomach, esophageal, colorectal, or pancreatic cancers that have a specific protein (MUC17). The main goal was to check safety and find the best dose. The trial was stopped early, and only 58 people t…

This study aimed to test the safety and effectiveness of new drugs for men with a type of advanced prostate cancer that no longer responds to hormone therapy. It enrolled 65 adults with confirmed cancer. The study was terminated early, so results are limited.

This study tested an investigational drug called daxdilimab in 72 adults with moderate-to-severe discoid lupus erythematosus (DLE), a skin condition that causes scarring and hair loss. The goal was to see if the drug could reduce disease activity compared to a placebo. However, t…

This early-phase study tested the safety and tolerability of a new drug called AMG 378 in 48 healthy adults aged 18 to 55. Participants received either single or multiple doses of the drug or a placebo, and researchers monitored side effects and how the drug moved through the bod…